吡咯替尼联合卡培他滨治疗Her-2阳性脑转移乳腺癌患者的临床效果  

Clinical study of Pyrrolotinib combined with Capecitabine in the treatment of Her-2 positive brain metastatic breast cancer

作　　者：莫淑芬 钟海鸣[1] 许靖靖 郁德杰 MO Shufen;ZHONG Haiming;XU Jingjing;YU Dejie(Department of Oncology,Guangdong Agricultural Reclamation Central Hospital,Guangdong Province,Zhanjiang 524000,China)

机构地区：[1]广东省农垦中心医院肿瘤内科,广东湛江524000

出　　处：《中国当代医药》2022年第36期83-85,89,共4页China Modern Medicine

基　　金：广东省湛江市科技计划项目(2020B01201)。

摘　　要：目的 研究吡咯替尼联合卡培他滨治疗人表皮生长因子受体-2(Her-2)阳性脑转移乳腺癌(BC)患者的临床效果。方法 选取2019年4月至2020年3月于广东省农垦中心医院治疗的40例Her-2阳性脑转移BC患者作为研究对象,按随机数字表法将其分为两组,每组各20例。对照组患者采用卡培他滨治疗,观察组患者采用卡培他滨与吡咯替尼联合治疗。21 d为1个周期,两组患者均连续治疗2个周期。比较两组患者的临床疗效、无疾病进展生存期(PFS)、总生存期(OS)及不良反应发生情况。结果 观察组患者的治疗疾病控制率(DCR)高于对照组,差异有统计学意义(P<0.05);观察组患者的PFS、OS长于对照组,差异有统计学意义(P<0.05);两组患者的各项不良反应发生率比较,差异无统计学意义(P>0.05)。结论 Her-2阳性脑转移BC患者采用吡咯替尼、卡培他滨联合治疗可延缓病情进展,提高DCR,延长患者的PFS及OS,临床应用安全可靠。Objective To study the clinical effect of Pyrrolotinib combined with Capecitabine in the treatment of human epidermal growth factor receptor-2(Her-2) positive brain metastatic breast cancer(BC). Methods A total of 40 patients with Her-2 positive brain metastasis BC treated in Guangdong Agricultural Reclamation Central Hospital from April 2019 to March 2020 were selected as subjects, and the patients were divided into two groups with 20 cases in each group according to random number table method. The control group was treated with Capecitabine, and the observation group was treated with Pyrrolotinib combined with Capecitabine. The clinical efficacy, progression free survival(PFS), overall survival(OS)and adverse reactions were compared between the two groups. Results The disease control rate(DCR) in the observation group was higher than that in the control group, and the difference was statistically significant(P<0.05). The PFS and OS of the observation group were longer than those of the control group, and the differences were statistically significant(P<0.05).There were no significant differences in the incidence rates of adverse reactions between the two groups(P >0.05).Conclusion The combined treatment of Pyrrolidine and Capecitabine in Her-2 positive patients with brain metastases from BC can delay the progress of the disease, improve DCR, and prolong PFS and OS. The clinical application is safe and reliable.

关 键 词：乳腺癌 脑转移 人表皮生长因子受体-2阳性 吡咯替尼 卡培他滨 生存期 不良反应 

分 类 号：R737.9[医药卫生—肿瘤]